On August 6, 2021 Sysmex reported that Summary of Consolidated Financial Results [ IFRS ] for the First Three Months of the Fiscal Year Ending March 31, 2022(Press release, Sysmex, AUG 6, 2021, View Source [SID1234586019])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
1. Results for the First Three Months of the Fiscal Year Ending March 31, 2022
(1) Operating results
(2) Financial condition
2. Dividend
3. Financial Forecast for the Year Ending March 31, 20224.
Other Information
(1) Changes in significant consolidated subsidiaries (which resulted in changes in scope of consolidation):
No (2) Changes in accounting policies and accounting estimates
1) Changes in accounting policies required by IFRS:
No 2) Other changes in accounting policies: No 3) Changes in accounting estimates:
No (3) Number of outstanding stock (common stock)
1) Number of outstanding stock at the end of each fiscal period (including treasury stock): 209,458,432 shares as of Jun. 30, 2021; 209,443,232 shares as of Mar. 31, 2021 2) Number of treasury stock at the end of each fiscal period: 446,952 shares as of Jun. 30, 2021; 446,876 shares as of Mar. 31, 2021 3) Average number of outstanding stock for each period (cumulative): 209,003,218 shares for the three months ended Jun. 30, 2021 208,839,381 shares for the three months ended Jun. 30, 2020
Note: Quarterly summaries of financial results are excluded from quarterly reviews. * Explanation regarding the appropriate use of financial forecast and other information
1. Basic earnings per share have been revised from the figures indicated in the consolidated financial forecast announced on May 12, 2021, in accordance with changes in the number of shares of outstanding stock and treasury stock. No other figures in the financial forecast have been revised.
2. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to "3) Consolidated financial forecast" within
"1. Qualitative information on quarterly financial results" on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
3. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Friday, August 6, 2021.